GLI3 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), SETD7 can specifically methylate the Gli3 at K436 and K595 sites, increasing the stability and DNA binding ability of Gli3, thereby enhancing the activation of Shh signaling.